New drug pricing plans will ‘damage UK biotech’
August 16, 2013Research and Development, Sales and Marketing BIA, Hunt, NHS, VBP, bates, biotech
The BioIndustry Association is warning that the government’s new drug pricing scheme could put future investment in the UK’s biotech …
Boehringer to shut down Petersburg chemicals facility
August 16, 2013Manufacturing and Production, Sales and Marketing Boehringer, Petersburg
Boehringer Ingelheim has conceded defeat in its search for a buyer for its chemicals facility in Petersburg, US, and is …
Price cut not enough for Pfizer’s Xalkori
August 16, 2013Sales and Marketing NICE, Pfizer, Xalkori, lung cancer
In final draft guidance NICE has rejected Pfizer’s new lung cancer drug Xalkori because of its high cost. The Institute …
Pharmstandard buys Singapore API firm to guarantee supply
August 16, 2013Manufacturing and Production OTC, Pharmstandard, bever
Russia’s largest drug company Pharmstandard has agreed a $590 million deal to buy the Singapore-based supplier of active pharmaceutical ingredients …
Cadence appoints Laureen DeBuono to its Board
August 16, 2013Manufacturing and Production, Medical Communications, Research and Development DeBuono, cadence
Biopharma firm Cadence Pharmaceuticals has appointed Laureen DeBuono to its Board of directors. “We are very pleased to welcome Ms …
GSK and Roche get EU breast cancer indication
August 15, 2013Sales and Marketing GSK, Herceptin, Roche, Tyverb, Xeloda, breast cancer
The European Commission has granted a new indication for the use of GSK’s breast cancer drug Tyverb in combination with …
Celgene’s multiple myeloma pill launched in UK
August 15, 2013Sales and Marketing Celgene, Velcade, low, myeloma
Celgene’s new oral blood cancer drug pomalidomide has been launched in the UK and Ireland as a third line treatment …
ABPI publishes trial disclosure ‘toolkit’
August 15, 2013Medical Communications, Sales and Marketing ABPI, EFPIA, Goldacre, transparency
The ABPI has today launched a new clinical trial disclosure toolkit to help pharma companies meet data transparency requirements. The …
Astellas hires senior VP from rival Takeda
August 15, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Takeda, oncology
Astellas has appointed Claire Thom from fellow Japanese firm Takeda to be senior vice president of its global oncology development. …
HIV pill Tivicay gains FDA approval
August 14, 2013Sales and Marketing FDA, GSK, Tivicay, ViiV
ViiV and partner GlaxoSmithKline’s new HIV drug Tivicay has been shown the FDA’s green light for distribution in the US. …
Phoenix from the flames for Lilly cancer drug
August 14, 2013Research and Development, Sales and Marketing NSCLC, lilly, lung cancer, necitumumab
A drug that once looked doomed to fail has shocked analysts by helping late-stage lung cancer patients live longer. Necitumumab …
New president and chief executive for EMMES
August 14, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMMES
Research support firm The EMMES Corporation has announced that its executive VP Dr Anne Lindblad has been promoted to president …
FDA project will examine abuse-resistant formulations
August 13, 2013Manufacturing and Production API, CDC, FDA
The FDA is seeking tenders for a research project to examine how effective tamper-resistant formulations of opioid analgesics really are …
The new NHS: a marriage of inconvenience?
August 13, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CCG, NHS England, andy lee, market access, quarry house
As NHS England tries to squeeze more money out of the healthcare budget to pay for specialist commissioning, Andy Lee …
Rebrand for Just:: comms agency
August 13, 2013Medical Communications Just:: Health
London-based healthcare agency Just:: Health PR has changed its name to Just:: Health Communications. The move is in response to …
Vical melanoma drug dropped
August 13, 2013Research and Development, Sales and Marketing Vical, allovectin, melanoma
Vical has abandoned trials of a late-stage drug for the deadliest form of skin cancer after the treatment failed to …
Bribery ‘routine’ for pharma in China
August 13, 2013Sales and Marketing BBC, China, GSK, Sanofi, bribery, drug reps
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
